Cuscuta epithymum Murr. crude extract pre-conditioning protects C6 cells from L-glutamate-induced neurotoxicity.
Crude extract
Cuscuta epithymum Murr.
Fractions
MDA
Neuroprotective
Phenolic content
ROS
SOD
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
22 Dec 2022
22 Dec 2022
Historique:
received:
10
08
2022
accepted:
02
12
2022
entrez:
22
12
2022
pubmed:
23
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
Cuscuta epithymum Murr. (C. epithymum), as an herbal medicine, has played an anti-cancerous role in various studies; however, its possible neuroprotective effects have been neglected. Here, we aimed to investigate the protective effects of C. epithymum seeds crude extract and different fractions on rat glioblastoma cells (C6) in L-glutamate oxidative condition. Initially, the total phenolic content of C. epithymum crude extract and the fractions (all produced by maceration method) was determined. Subsequently, C6 cells were pre-treated with the various concentrations of crude extract and fractions 24 h before L-glutamate exposure. Likewise, C6 cells were treated with the same concentrations of crude extract and fractions 24 h after exposure to L-glutamate. The cell viability and morphology were compared in crude extract and fractions groups, then superoxide dismutase (SODs) activity, reactive oxygen species (ROS), and malondialdehyde (MDA) levels were measured. The flow cytometry test was used to study C. epithymum crude extract's effects on the cell cycle and also to quantify the apoptosis, necrosis, and live cells population in different groups. C. epithymum crude extract and fractions (hexanoic, dichloromethanolic, and methanolic) had concentration-dependent cytotoxicity (IC50:126.47, 2101.96, 140.97, and 218.96 µg/ml, respectively). The crude extract and methanolic fraction contained phenolic compounds (55.99 ± 2.795 and 50.80 ± 2.969 mg gallic acid/g extract), while in hexanoic and dichloromethanolic fractions, the phenolic content was undetectable. In the cell viability assay, in comparison to fractions, the crude extract showed a more protective effect against glutamate-induced oxidative condition (P < 0.0001). The crude extract increased the SODs activity (P < 0.001) and decreased MDA and ROS levels (P < 0.0001) in comparison to the glutamate group. The crude extract significantly increased the population of cells in G1 (from 63.04 to 76.29) and decreased the percentage of cells in G2 (from 11.56 to 6.7) and S phase (from 25.4 to 17.01). In addition, it decreased the apoptotic and necrotic cell populations (from 34 to 17.1) and also increased the percentage of live cells (from 66.8 to 83.4 percent) in the flow cytometry test. C. epithymum crude extract plays a neuroprotective role by activating the defense mechanisms in cell against the oxidative condition.
Sections du résumé
BACKGROUND
BACKGROUND
Cuscuta epithymum Murr. (C. epithymum), as an herbal medicine, has played an anti-cancerous role in various studies; however, its possible neuroprotective effects have been neglected. Here, we aimed to investigate the protective effects of C. epithymum seeds crude extract and different fractions on rat glioblastoma cells (C6) in L-glutamate oxidative condition.
METHODS
METHODS
Initially, the total phenolic content of C. epithymum crude extract and the fractions (all produced by maceration method) was determined. Subsequently, C6 cells were pre-treated with the various concentrations of crude extract and fractions 24 h before L-glutamate exposure. Likewise, C6 cells were treated with the same concentrations of crude extract and fractions 24 h after exposure to L-glutamate. The cell viability and morphology were compared in crude extract and fractions groups, then superoxide dismutase (SODs) activity, reactive oxygen species (ROS), and malondialdehyde (MDA) levels were measured. The flow cytometry test was used to study C. epithymum crude extract's effects on the cell cycle and also to quantify the apoptosis, necrosis, and live cells population in different groups.
RESULTS
RESULTS
C. epithymum crude extract and fractions (hexanoic, dichloromethanolic, and methanolic) had concentration-dependent cytotoxicity (IC50:126.47, 2101.96, 140.97, and 218.96 µg/ml, respectively). The crude extract and methanolic fraction contained phenolic compounds (55.99 ± 2.795 and 50.80 ± 2.969 mg gallic acid/g extract), while in hexanoic and dichloromethanolic fractions, the phenolic content was undetectable. In the cell viability assay, in comparison to fractions, the crude extract showed a more protective effect against glutamate-induced oxidative condition (P < 0.0001). The crude extract increased the SODs activity (P < 0.001) and decreased MDA and ROS levels (P < 0.0001) in comparison to the glutamate group. The crude extract significantly increased the population of cells in G1 (from 63.04 to 76.29) and decreased the percentage of cells in G2 (from 11.56 to 6.7) and S phase (from 25.4 to 17.01). In addition, it decreased the apoptotic and necrotic cell populations (from 34 to 17.1) and also increased the percentage of live cells (from 66.8 to 83.4 percent) in the flow cytometry test.
CONCLUSION
CONCLUSIONS
C. epithymum crude extract plays a neuroprotective role by activating the defense mechanisms in cell against the oxidative condition.
Identifiants
pubmed: 36550546
doi: 10.1186/s12906-022-03816-6
pii: 10.1186/s12906-022-03816-6
pmc: PMC9773566
doi:
Substances chimiques
Plant Extracts
0
Glutamic Acid
3KX376GY7L
Reactive Oxygen Species
0
Phenols
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
335Informations de copyright
© 2022. The Author(s).
Références
Iran J Basic Med Sci. 2019 Nov;22(11):1225-1252
pubmed: 32128087
J Pharmacol Exp Ther. 2017 Jan;360(1):201-205
pubmed: 27754930
Neurochem Res. 2011 Mar;36(3):355-66
pubmed: 21140288
Nat Neurosci. 2002 Jul;5(7):633-9
pubmed: 12085093
Br J Pharmacol. 2007 Jan;150(1):5-17
pubmed: 17088867
AJNR Am J Neuroradiol. 2001 Nov-Dec;22(10):1813-24
pubmed: 11733308
Front Cell Neurosci. 2015 Mar 17;9:91
pubmed: 25852482
Curr Drug Discov Technol. 2020;17(3):332-337
pubmed: 30394211
Naunyn Schmiedebergs Arch Pharmacol. 2010 Jan;381(1):73-81
pubmed: 19936711
Avicenna J Phytomed. 2021 Nov-Dec;11(6):645-656
pubmed: 34804901
J Neurosci. 2005 Aug 3;25(31):7101-10
pubmed: 16079392
Eur J Pharmacol. 2002 Jul 5;447(2-3):239-46
pubmed: 12151015
Zhong Yao Cai. 2006 Oct;29(10):1051-5
pubmed: 17326406
Res Pharm Sci. 2014 Mar-Apr;9(2):115-22
pubmed: 25657780
Chem Pharm Bull (Tokyo). 2021;69(9):832-839
pubmed: 34470947
J Neural Transm (Vienna). 2014 Aug;121(8):799-817
pubmed: 24578174
Curr Neuropharmacol. 2013 Mar;11(2):171-85
pubmed: 23997752
Chem Cent J. 2014 Aug 22;8(1):48
pubmed: 25246942
Antioxid Redox Signal. 2013 Feb 10;18(5):522-55
pubmed: 22667998
FEBS Lett. 2001 May 18;497(1):1-5
pubmed: 11376653
Cancer Res. 2021 Feb 1;81(3):552-566
pubmed: 33229341
Am J Physiol. 1997 Nov;273(5):R1771-8
pubmed: 9374822
Neurosci Behav Physiol. 2009 May;39(4):353-62
pubmed: 19340578
BMC Complement Altern Med. 2017 Jun 5;17(1):294
pubmed: 28583139